IRIS
FORMICA, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.012
AS - Asia 3.449
EU - Europa 2.430
SA - Sud America 537
Continente sconosciuto - Info sul continente non disponibili 446
AF - Africa 41
OC - Oceania 6
Totale 27.921
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.883
SG - Singapore 1.521
CN - Cina 621
IT - Italia 581
BR - Brasile 458
RU - Federazione Russa 425
HK - Hong Kong 369
VN - Vietnam 283
DE - Germania 261
UA - Ucraina 237
BD - Bangladesh 235
IE - Irlanda 219
FR - Francia 156
JP - Giappone 124
GB - Regno Unito 117
FI - Finlandia 107
SE - Svezia 94
PL - Polonia 84
CA - Canada 64
KR - Corea 62
IN - India 57
NL - Olanda 43
ID - Indonesia 36
AR - Argentina 35
MX - Messico 33
IQ - Iraq 22
AT - Austria 21
ES - Italia 21
BE - Belgio 17
TR - Turchia 14
PK - Pakistan 13
EC - Ecuador 12
SA - Arabia Saudita 12
ZA - Sudafrica 12
AE - Emirati Arabi Uniti 8
EU - Europa 8
MY - Malesia 8
PH - Filippine 8
CO - Colombia 7
EG - Egitto 7
LT - Lituania 7
NP - Nepal 7
PY - Paraguay 7
TH - Thailandia 7
CL - Cile 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
JM - Giamaica 6
AL - Albania 5
AU - Australia 5
CH - Svizzera 5
HN - Honduras 5
IL - Israele 5
MA - Marocco 5
TN - Tunisia 5
BG - Bulgaria 4
KE - Kenya 4
KG - Kirghizistan 4
NI - Nicaragua 4
UY - Uruguay 4
UZ - Uzbekistan 4
JO - Giordania 3
LB - Libano 3
PE - Perù 3
QA - Qatar 3
RO - Romania 3
VE - Venezuela 3
AZ - Azerbaigian 2
BY - Bielorussia 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
IR - Iran 2
KW - Kuwait 2
MN - Mongolia 2
MT - Malta 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PT - Portogallo 2
RS - Serbia 2
SI - Slovenia 2
SV - El Salvador 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BM - Bermuda 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GF - Guiana Francese 1
GY - Guiana 1
HT - Haiti 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
Totale 27.475
Salva come PNG Salva come JPEG
Città #
Woodbridge 5.250
Wilmington 4.710
Houston 4.626
Singapore 816
Fairfield 573
Ashburn 500
San Jose 489
Hong Kong 363
Chandler 342
Ann Arbor 336
Beijing 264
Council Bluffs 264
Seattle 263
Cambridge 215
Jacksonville 213
Dublin 204
Rome 167
Medford 162
New York 161
Dallas 152
Santa Clara 143
Los Angeles 128
The Dalles 128
Tokyo 110
Ho Chi Minh City 92
Dearborn 89
Engelhard 85
Buffalo 77
Lawrence 72
Hanoi 68
Menlo Park 67
Kraków 64
Moscow 64
Milan 59
Lauterbourg 56
San Diego 46
Chicago 45
Helsinki 41
Saint Petersburg 35
Boardman 34
Orem 34
Redondo Beach 33
São Paulo 33
Zhengzhou 33
Frankfurt am Main 25
Jakarta 25
Falls Church 24
Chennai 19
London 19
Montreal 19
Mülheim 19
Nuremberg 19
Brooklyn 18
Phoenix 18
Brussels 17
Mexico City 17
North Bergen 16
Salt Lake City 16
San Francisco 16
Warsaw 16
Lappeenranta 15
Atlanta 14
Rio de Janeiro 14
Belo Horizonte 13
Cagliari 13
Detroit 13
Porto Alegre 13
Turin 13
Denver 12
Boston 11
Munich 11
Toronto 11
Mumbai 10
Nanjing 10
Norwalk 10
Seoul 10
Shanghai 10
Stockholm 10
Amsterdam 9
Bologna 9
Brasília 9
Columbus 9
Haiphong 9
Hangzhou 9
Hefei 9
Miami 9
Redwood City 9
Vienna 9
Charlotte 8
Cleveland 8
Curitiba 8
Kunming 8
Manchester 8
Naples 8
Palo Alto 8
Tampa 8
Vancouver 8
Washington 8
Johannesburg 7
Mannheim 7
Totale 22.406
Salva come PNG Salva come JPEG
Nome #
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report 532
Preclinical studies on detection of circulating melanoma cells in patients: Telomerase as a recognition marker of malignancy 506
Drug-induced increase of carcinoembryonic antigen expression in cancer cells 492
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients 481
Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass 473
Effects of conventional therapeutic interventions on the number and function of regulatory T cells 469
Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients 466
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies 465
Biological and predictive role of ERCC1 polymorphisms in cancer 465
TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy 459
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio 456
Prognostic value of glycated hemoglobin in colorectal cancer 455
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 453
Immune reaction and colorectal cancer: friends or foes? 453
Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer 452
Thromboembolic events in patients treated with anti-angiogenic drugs 448
Are there alternative ways to quantify the real benefit of novel agents in oncology? - The 'death pace' 436
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer 432
Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression 430
Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience 429
Family history of cancer in patients with gastric cancer 427
The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience 424
VEGF gene promoter polymorphisms and risk of VTE in chemotherapytreated cancer patients 419
CD26: a multi-purpose pharmacological target 418
Insulinemia and the risk of breast cancer and its relapse 417
VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea 412
Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle 411
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy 411
Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin 407
Up-regulation of carcinoembryonic antigen (CEA) expression by staurosporine in circulating colon cancer cells 406
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 399
Targeted therapy in first line treatment of RAS wild type colorectal cancer 396
Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges 395
A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes 393
Caregiver distress in the early phases of cancer 391
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients 391
Prognostic significance of serum adipokine levels in colorectal cancer patients 388
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B) 384
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches 382
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab 379
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 375
Non-steroidal anti-inflammatory drugs in cancer prevention and therapy 373
Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol 353
Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome 350
Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer 350
A novel K-ras mutation in colorectal cancer. A case report and literature review 349
Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy 343
Clinical significance of glycemic parameters on venous thromboembolism risk preDiction in gastrointestinal cancer 326
Chemotherapy in patients with hereditary angioedema 326
Case report of a patient with breast metastasis from gastric cancer treated with paclitaxel and ramucirumab plus regional hyperthermia 316
Cancer patients in the emergency department: A "nightmare" that might become a virtuous clinical pathway 310
Histotype influences emergency presentation and prognosis in colon cancer surgery 255
Relevance of computed tomography and magnetic resonance imaging for penile metastasis after prostatectomy: uncommon case report and brief review of the literature 239
Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2 216
A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel 186
Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors 181
Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors 173
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset 172
Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt 164
Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer 163
Clinical utility of plasma KRAS, NRAS and BRAF mutational analysis with real time PCR in metastatic colorectal cancer patients -The importance of tissue/plasma discordant cases 140
Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study 136
Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events? 136
KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis 133
Irinotecan or oxaliplatin: which is the first move for the mate? 124
Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care 118
Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy? 116
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 116
Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy 116
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis 111
The effects of association of topical polydatin improves the preemptive systemic treatment on EGFR inhibitors cutaneous adverse reactions 111
Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study 107
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ?BRAF BeCool? study 106
Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice? 106
HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling 105
A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma 105
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response 103
Untailored vs. Gender- and Body-Mass-Index-Tailored Skeletal Muscle Mass Index (SMI) to Assess Sarcopenia in Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) 99
Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview 97
Gender differences in cancer-associated venous thromboembolism 97
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 96
Solitary metachronous gastric metastasis from pulmonary adenocarcinoma: Report of a case 94
Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age 94
Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation 92
MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review 90
Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer = Ruolo dell’infiammazione e delle cellule CD45RO+CD8+ nei tumori colorettali metastatici 89
Concordance of blood-based and normal tissue-based dihydropyrimidine dehydrogenase (DPYD) genotyping 86
Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy [3] 85
Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer 83
Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer = Ruolo dell’infiammazione e delle cellule CD45RO+CD8+ nei tumori colorettali metastatici 81
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study 78
Circulating Hepcidin Levels Are an Independent Predictor of Survival in Microsatellite Stable Metastatic Colorectal Cancer Patient Candidates for Standard First-Line Treatment 77
Adjuvant therapy for very young women with breast cancer: Response according to biologic and endocrine features 74
Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial–Mesenchymal Transition and Correlates with Progression of the Disease 72
PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials 72
Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data 70
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 69
Issues and promises of bevacizumab in prostate cancer treatment 67
Obesity and common pathways of cancer and cardiovascular disease 66
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 63
Totale 26.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.769
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022823 0 81 38 48 44 70 75 65 67 86 49 200
2022/2023936 87 73 21 113 116 228 73 56 82 10 42 35
2023/2024567 40 16 36 20 33 103 176 51 7 4 5 76
2024/20252.499 56 488 207 125 33 182 165 160 443 254 203 183
2025/20264.996 367 278 630 387 406 192 496 583 530 403 437 287
2026/2027554 303 251 0 0 0 0 0 0 0 0 0 0
Totale 27.921